Profile data is unavailable for this security.
About the company
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in CNY (TTM)2.23bn
- Net income in CNY-947.63m
- Incorporated2008
- Employees3.00k
- LocationRemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
- Phone+86 5 353573685
- Fax+86 5 356113517
- Websitehttps://www.remegen.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Joinn Laboratories China Co Ltd | 1.67bn | 225.09m | 25.89bn | 2.65k | 109.54 | 3.44 | -- | 15.52 | 0.3405 | 0.3405 | 2.37 | 10.84 | 0.175 | 0.7843 | 6.03 | 629,011.80 | 2.36 | 6.60 | 2.72 | 7.92 | 24.63 | 41.87 | 13.47 | 25.98 | 3.06 | -- | 0.0039 | 23.59 | -15.07 | 25.85 | -81.34 | -16.89 | 16.27 | -19.46 |
| Wuhan Healthgen Biotechnology Corp | 23.39m | -160.81m | 26.32bn | 215.00 | -- | 52.97 | -- | 1,125.54 | -0.4498 | -0.4498 | 0.0654 | 1.39 | -- | -- | -- | 131,386.80 | -- | -- | -- | -- | 41.12 | -- | -687.60 | -- | 0.359 | -30.87 | 0.5497 | -- | 3.92 | -- | 19.04 | -- | -- | -- |
| Biocytogen Phrmutcls (Beijing) Co Ltd | 1.33bn | 249.94m | 28.91bn | 1.28k | 128.11 | 32.82 | 74.44 | 21.71 | 0.5593 | 0.5593 | 2.98 | 2.18 | -- | -- | -- | 1,215,939.00 | -- | -- | -- | -- | 76.56 | -- | 18.77 | -- | 1.11 | 14.77 | 0.5281 | -- | 36.76 | -- | 108.76 | -- | -- | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 4.76bn | 1.98bn | 43.02bn | 1.42k | 21.70 | 6.62 | -- | 9.04 | 4.41 | 4.41 | 10.57 | 14.44 | 0.7497 | 5.75 | 13.98 | 3,357,423.00 | 31.24 | 10.89 | 34.76 | 11.75 | 95.37 | 96.19 | 41.68 | 27.72 | 5.34 | -- | 0.0006 | 24.71 | 76.29 | 462.87 | 121.97 | -- | 24.77 | -- |
| RemeGen Co Ltd | 2.23bn | -947.63m | 50.84bn | 3.00k | -- | 24.64 | -- | 22.82 | -1.75 | -1.75 | 4.10 | 4.12 | 0.3812 | 0.541 | 6.40 | 742,854.40 | -16.21 | -19.20 | -27.09 | -23.96 | 82.97 | 81.06 | -42.54 | -87.98 | 0.7278 | -9.93 | 0.4848 | -- | 58.54 | 223.78 | 2.84 | -- | 32.40 | -- |
Data as of Feb 10 2026. Currency figures normalised to RemeGen Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
28.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 9.38m | 5.75% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 8.43m | 5.17% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 6.06m | 3.72% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 4.86m | 2.98% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2025 | 4.09m | 2.51% |
| Allianz Global Investors Asia Pacific Ltd.as of 31 Oct 2025 | 3.12m | 1.91% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 3.12m | 1.91% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.95m | 1.81% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 2.55m | 1.57% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 2.28m | 1.40% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
